SCHEMBL13997679

SCHEMBL13997679

O=C(O)c1c(Cl)c2ccccc2[nH]c1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.72
TDP1 Q9NUW8 1/20 0.72
LMNA P02545 3/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
IDE P14735 1/20 0.49
MPI P34949 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
HSD17B10 Q99714 3/20 0.48
PARP1 P09874 2/20 0.48
CYP1A2 P05177 2/20 0.48
TNKS O95271 1/20 0.48
GPR3 P46089 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
PARP15 Q460N3 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5166808 0.85 KDM4E (0.56) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL31146399 0.85 KDM4E (0.56) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL29415434 0.84 KDM4E (1.00) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL2805779 0.84 KDM4E (1.00) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL1621957 0.81 KDM4E (0.69) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL3985154 0.81 KDM4E (0.74) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL1620204 0.79 KDM4E (0.72) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL30388663 0.79 KDM4E (0.72) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL1037203 0.79 KDM4E (0.72) KDM4ETDP1LMNAMEN1KMT2A
SCHEMBL15067394 0.79 KDM4E (0.72) KDM4ETDP1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110041306-A 4- hydroxyl -2- quinolone-nitrogen-(4- quinazolinone) -3- carboxamides derivatives 中国医学科学院药物研究所 2019-07-23 CN disclosed
CN-102015705-B Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2013-11-13 CN disclosed
CN-102015705-A Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
US-20080311150-A1 Novel sequences encoding hepatitis C virus glycoproteins DUMONCEAUX JULIE 2008-12-18 US disclosed
US-7361503-B2 Sequences encoding hepatitis C virus glycoproteins ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2008-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311150-A1 Novel sequences encoding hepatitis C virus glycoproteins HAVCR2, EEA1, SELPLG KDM4E 3908/4885TDP1 3943/4885LMNA 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.